Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Purpose: IL6 is important for the growth and survival of myeloma cells. This study evaluated blocking IL6 with siltuximab to delay the transition from high-risk smoldering multiple myeloma (SMM) to multiple myeloma. Patients and Methods: In a randomized, double-blind, placebo-controlled, multicenter study, 85 patients with high-risk SMM were randomized to 15 mg/kg siltuximab (43 patients) or placebo (42 patients). The primary endpoint was 1-year progression-free survival (PFS) rate, based on IMWG CRAB criteria. Secondary endpoints included progressive disease indicator rate, PFS, and safety. Results: Median age was 62 years (range: 21–84); 57% were male and 87% had a baseline Eastern Cooperative Oncology Group score of 0. The 1-year PFS rate was 84.5% (siltuximab) and 74.4% (placebo). After a median follow-up of 29.2 months, 32.6% of PFS events occurred with siltuximab and 42.9% with placebo. Median PFS was not reached with siltuximab but was 23.5 months with placebo [HR 0.50 (95% confidence interval, 0.24–1.04); P = 0.0597]. The safety profile of siltuximab was comparable with placebo. Most adverse events in the siltuximab group were grade 2/3; the most common serious adverse events were infections/infestations, and renal/urinary disorders. Mortality was low in both groups (3 deaths in the siltuximab group and 4 in the placebo group). Conclusions: Although this study did not meet the prespecified protocol hypothesis criteria, data suggest that siltuximab may delay the progression of high-risk SMM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921 · cited 3×
“At the time of study protocol development, high-risk SMM was defined as patients having both serum monoclonal M-protein 3 g/dL and bone marrow plasma cells (BMPC) 10% (4).”
BackgroundInfluential
Cited by
Interleukins in cancer: from biology to therapy
Briukhovetska, D., Dörr, J., Endres, S., Libby, P., Dinarello, C. A., & Kobold, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00363-z · Cited by 781
Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma
Harmer, D., Falank, C., & Reagan, M. R. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00788 · Cited by 307
Landgren, C. O., Chari, A., Cohen, Y. C., Spencer, A., Voorhees, P., Estell, J. A., Sandhu, I., Jenner, M. W., Williams, C., Cavo, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0718-z · Cited by 102
Self-citationTargeting NF-κB Signaling for Multiple Myeloma
Wong, A. H.-H., Shin, E. M., Tergaonkar, V., & Chng, W.-J. (2020) · Cancers · doi:10.3390/cancers12082203 · Cited by 42
Impact of Age-, Cancer- and Treatment-Driven Inflammation on T Cell Function and Immunotherapy
Quinn, K. M., Kartikasari, A. E. R., Cooke, R. E., Koldej, R. M., Ritchie, D. S., & Plebanski, M. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0520-466r · Cited by 31
Metadata
- Authors
- Brighton, T. A., Khot, A., Harrison, S. J., Ghez, D., Weiss, B. M., Kirsch, A., Magen, H., Gironella, M., Oriol, A., Streetly, M., Kranenburg, B., Qin, X., Bandekar, R., Hu, P., Guilfoyle, M., Qi, M., Nemat, S., & Goldschmidt, H.
- Venue
- Clinical Cancer Research
- Published
- 2019-07-01
- Volume
- 25
- Issue
- 13
- Pages
- 3772-3775
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2923671051
- Cited by
- 71
- References
- 3
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-3470
- The paper
- Brighton, T. A., Khot, A., Harrison, S. J., Ghez, D., Weiss, B. M., Kirsch, A., Magen, H., Gironella, M., Oriol, A., Streetly, M., Kranenburg, B., Qin, X., Bandekar, R., Hu, P., Guilfoyle, M., Qi, M., Nemat, S., & Goldschmidt, H. (2019). Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-3470
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.